drugset / Trial / NCT03187288
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. The purpose of this phase 1 study is to see how safe and tolerable the study drug is and to determine the best dose (maximum tolerated dose or recommended phase 2 dose) that can be given in this patient population.
Timeline
- Start
- 2018-05-25
- Primary completion
- 2021-06-30
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCIFISERTIB | Small molecule | 64 mg | Oral |
| Subject | OCIFISERTIB | Small molecule | 96 mg | Oral |
| Subject | OCIFISERTIB | Small molecule | 128 mg | Oral |
| Subject | OCIFISERTIB | Small molecule | 160 mg | Oral |
| Subject | OCIFISERTIB | Small molecule | 192 mg | Oral |
| Subject | OCIFISERTIB | Small molecule | 224 mg | Oral |